8-K: SI-BONE Q2 2025 Revenue Up 21.7%, Raises Guidance

SI-BONE, Inc. reported strong second-quarter 2025 financial results with significant revenue growth and positive Adjusted EBITDA, leading to raised full-year guidance.

Summary

• Worldwide revenue reached $48.6 million in Q2 2025, representing a 21.7% increase from the prior year period.
• U.S. revenue was $46.4 million, growing 22.8% year-over-year, driven by strong underlying procedure demand.
• Gross margin improved by 80 basis points to 79.8% in Q2 2025.
• Net loss improved by 31.2% to $6.2 million, or $0.14 per diluted share, compared to $8.9 million in Q2 2024.
• Achieved positive Adjusted EBITDA of $1.0 million in Q2 2025, a significant improvement from a $2.7 million loss in the prior year period.
• Generated $1.1 million in net cash during the quarter, reversing a $6.3 million net cash usage in the corresponding period of 2024.
• Cash and equivalents stood at $145.5 million as of June 30, 2025.
• Active U.S. physicians grew by approximately 25% to 1,440.
• Trailing 12-month average revenue per territory increased by approximately 23% to $2.1 million.
• CMS confirmed the New Technology Add-On Payment (NTAP) for iFuse TORQ TNT, effective October 1, 2025, providing an additional amount up to $4,136 per procedure.
• CMS proposed the continuation of the Transitional Pass-Through Payment for Granite for CY2026.
• The company launched iFuse TORQ across Europe in July 2025.
• Full-year 2025 worldwide revenue guidance was raised to a range of $195 million to $198 million, implying 17% to 18% year-over-year growth.
• Full-year 2025 gross margin is estimated to be between 78.5% and 79.0%.
• Operating expenses are anticipated to grow at approximately 10% at the mid-point of the revenue guidance for full-year 2025.
• The company expects to deliver positive Adjusted EBITDA for the full year 2025.
• Anthony Recupero, President, Commercial Operations, announced his retirement effective February 15, 2026, and will transition to a 12-month advisory role starting February 16, 2026.
• Nikolas Kerr, Senior Vice President of Product, Marketing and Business Development, was appointed Chief Commercial Officer to succeed Mr. Recupero, effective February 16, 2026.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth, achieved positive Adjusted EBITDA and cash flow breakeven, and raised its full-year guidance. Key operational metrics like physician adoption and revenue per territory also showed strong growth. Favorable CMS reimbursement updates further bolster the outlook. The management transition appears well-planned.

Positives

• Worldwide revenue grew 21.7% to $48.6 million, demonstrating strong market demand.
• U.S. revenue increased 22.8% to $46.4 million, indicating robust domestic performance.
• Gross margin improved by 80 basis points to 79.8%, reflecting enhanced operational efficiency.
• Net loss significantly improved by 31.2% to $6.2 million, moving closer to profitability.
• Achieved positive Adjusted EBITDA of $1.0 million, a substantial turnaround from a $2.7 million loss in the prior year period.
• Generated $1.1 million in net cash, reversing a prior year cash usage of $6.3 million and indicating improved cash flow management.
• Active U.S. physicians increased by approximately 25% to 1,440, showing strong physician adoption and engagement.
• Trailing 12-month average revenue per territory grew by approximately 23% to $2.1 million, highlighting effective commercial strategies.
• Raised full-year 2025 worldwide revenue guidance to $195 million $198 million, signaling confidence in continued growth.
• CMS confirmed the New Technology Add-On Payment (NTAP) for iFuse TORQ TNT, providing additional reimbursement up to $4,136, which is a significant market advantage.
• CMS proposed the continuation of the Transitional Pass-Through Payment for Granite for CY2026, ensuring continued favorable reimbursement.
• Successfully launched iFuse TORQ across Europe in July, expanding international market reach.

Negatives

• Despite significant improvements, the company still reported a net loss of $6.2 million.
• Operating expenses increased by 10.0% to $45.8 million, primarily driven by general commercial activity related to higher revenue, new product rollout, and elevated general and administrative spend.

Risks

• Ability to introduce and commercialize new products and indications.
• Ability to maintain favorable reimbursement for procedures using its products.
• Impact of any future economic weakness or deterioration in economic conditions on the ability and desire of patients to undergo elective procedures.
• Ability to manage risks to its supply chain.
• Future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment.
• Pace of the re-normalization of the healthcare operating environment, including the ability and desire of patients and physicians to undergo and perform procedures.

Future Outlook

SI-BONE expects continued robust engagement and expansion of its physician base, driven by innovation and new product adoption. The company anticipates sustained, profitable growth, with full-year 2025 worldwide revenue projected between $195 million and $198 million, gross margin between 78.5% and 79.0%, and positive adjusted EBITDA. They also expect continued favorable reimbursement for their products with CMS confirming NTAP for iFuse TORQ TNT and proposing continuation of Transitional Pass-Through Payment for Granite.

Management Comments

• "Our strong second-quarter performance highlights how our innovation-driven strategy continues to fuel robust engagement across our rapidly expanding physician base." Laura Francis, Chief Executive Officer.
• "We delivered double-digit procedure volume growth across all our U.S. target markets, propelled by accelerating adoption of our latest product launches and sustained demand for our proven solutions." Laura Francis, Chief Executive Officer.
• "Beyond top-line momentum, our consistent delivery of positive Adjusted EBITDA and achievement of cash flow breakeven this quarter underscore the power of our asset-light model and disciplined execution." Laura Francis, Chief Executive Officer.
• "He built the industry’s premier commercial organization, led the successful launch of multiple procedural solutions, and developed a world-class leadership team that positions us for enduring success." Laura Francis, Chief Executive Officer, on Tony Recupero.
• "I’m confident that the best is yet to come as we expand our platform, deepen physician engagement, and deliver sustained, profitable growth." Laura Francis, Chief Executive Officer.

Industry Context

The medical device sector, particularly in orthopedic and spine solutions, benefits from ongoing innovation and favorable reimbursement policies. SI-BONE's focus on sacropelvic disorders and minimally invasive surgery aligns with trends towards less invasive procedures and specialized solutions. The confirmation of NTAP and proposed continuation of Transitional Pass-Through Payment from CMS indicates a supportive regulatory and reimbursement environment for new technologies in this space, which is crucial for medical device companies. The European launch of iFuse TORQ suggests international expansion is a key growth driver.

Comparison to Industry Standards

• SI-BONE's 21.7% worldwide revenue growth and 22.8% U.S. revenue growth significantly outperform the average growth rates for established medical device companies, which often range from mid-single digits to low double-digits, indicating strong market penetration and adoption for their specialized products.
• Achieving positive Adjusted EBITDA of $1.0 million and cash flow breakeven is a notable milestone, especially for a company still reporting a net loss. This demonstrates improving operational efficiency and financial discipline, moving towards profitability, which is a positive signal compared to many growth-stage medical device firms that may still be heavily investing and incurring losses.
• The gross margin of 79.8% is exceptionally high, indicating strong pricing power and efficient production for their specialized devices. This is well above typical gross margins for many medical device companies, which can range from 60-75%.
• The increase in active U.S. physicians by approximately 25% and average revenue per territory by approximately 23% suggests effective commercial strategies and strong physician engagement, which are critical metrics for medical device adoption.
• The CMS NTAP for iFuse TORQ TNT and proposed pass-through for Granite are significant competitive advantages, providing additional reimbursement that can accelerate adoption compared to competitors without such specific payment pathways.
• While specific comparable companies are not named in the filing, SI-BONE's performance metrics suggest it is a leader in the minimally invasive SI joint fusion market, potentially outperforming smaller, less established players and competing effectively with larger orthopedic companies that may have broader portfolios but less specialized focus in this niche.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, improved profitability metrics (positive Adjusted EBITDA, cash flow breakeven), and a well-managed leadership transition.
• Employees: Positive for Nikolas Kerr and potentially other employees due to internal promotion and clear succession planning. Anthony Recupero's transition to an advisory role provides continued engagement.
• Customers (Physicians): Continued support and engagement through expanding physician base and new product launches (iFuse TORQ). Favorable reimbursement updates (NTAP, Pass-Through) make procedures more attractive.
• Suppliers: Potential for increased demand for components and materials due to revenue growth and new product rollouts.

Next Steps

• Anthony Recupero will remain an at-will employee in his current role and perform regular job duties until February 15, 2026.
• Anthony Recupero will transition to a 12-month advisory role starting February 16, 2026.
• Nikolas Kerr will assume the Chief Commercial Officer role effective February 16, 2026.
• The company will file the Retirement Letter and Consulting Agreement as an exhibit to its quarterly report on Form 10-Q for the quarter ended June 30, 2025.
• SI-BONE will host a conference call to discuss the second quarter 2025 financial results on Monday, August 4, 2025, at 4:30 P.M. Eastern Time.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in Q2 2025, significantly exceeding prior year results across key metrics including revenue growth, gross margin expansion, and a shift to positive Adjusted EBITDA and cash flow generation. The raised full-year guidance indicates strong confidence in continued momentum. Strategic operational achievements like increased physician adoption and favorable CMS reimbursement decisions (NTAP, pass-through) provide strong tailwinds. The planned and orderly executive succession further de-risks leadership transition. These factors collectively point to robust underlying business health and strong future growth prospects, making it a compelling investment.

Keywords

SI-BONE, SIBN, medical device, sacropelvic disorders, SI joint surgery, iFuse, iFuse TORQ, Granite, minimally invasive surgery, financial results, earnings, Q2 2025, revenue growth, EBITDA, cash flow, guidance, CMS, NTAP, commercial operations, executive retirement, chief commercial officer